Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Diagnostics firms developing tests for the novel coronavirus got two new tools from the US Food and Drug Administration on 29 May, as the agency released an emergency use authorization (EUA) template for tests using at-home sample collection kits, as well as a COVID-19 reference panel.
The voluntary EUA template makes recommendations for labs and commercial manufacturers hoping to submit EUA requests for molecular diagnostics using at-home sample collection kits. The 14-page document can be used to write EUAs discussing test kits that use saliva and nasal swab samples, while developers of potential tests using other sample types would need to contact the FDA individually.
In addition to providing such standard information as intended use and performance evaluation details, manufacturers completing the template are asked to discuss how patients will be selected for the test and who will write needed prescriptions, as well as how the sample will be protected during shipping. Further, the test kits should incorporate a control ensuring the collected sample is sufficient for testing.
“Home collection raises unique concerns about safety and accuracy – for example, can the sample be collected safely and properly by a layperson, can the sample be shipped in a way that’s stable to ensure an accurate result once it reaches the lab, among other factors – which is why these tests require FDA review, to ensure they work as they should and are safe for all involved.” – Jeff ShurenThe FDA authorized the first test kit allowing home sample collection in April, and a saliva-based at-home test kit followed in May. At least six tests using at-home sample collection have received EUAs. (Also see "FDA Authorizes First At-Home COVID-19 Saliva Sample Collection Kit" - Medtech Insight, 8 May, 2020.)
However, FDA device center director Jeff Shuren noted in a statement that the tests still pose additional risks. “Home collection raises unique concerns about safety and accuracy – for example, can the sample be collected safely and properly by a layperson, can the sample be shipped in a way that’s stable to ensure an accurate result once it reaches the lab, among other factors – which is why these tests require FDA review, to ensure they work as they should and are safe for all involved,” he said. “An at-home test that returns false results could be harmful to an individual patient, and hinder broader public health efforts to mitigate the spread of COVID-19.”
Separately, the agency announced the release of a COVID-19 (formally known as SARS-CoV-2) reference panel, which will give developers access to well-characterized reagents that can be used to compare the performance of different molecular diagnostic tests under the same conditions. Reagent panels are an extra step in the diagnostic development process that can help ensure test quality, validate new assays, calibrate tests and monitor assay performance, the agency said.
The new reference panel be available to commercial and lab developers who are working with the FDA through a pre-EUA process. The agency has provided similar reference panels in previous outbreaks, such as 2015’s Zika outbreak.
Medtech Insight: global medical technology news & analysis
By Ashley Yeo 13 Jul 2020
The UK will not control COVID-19 sustainably unless it adopts new ways of doing things, health minster Lord Bethell told...
Medtech Insight: global medical technology news & analysis
By Amanda Maxwell 10 Jul 2020
In the EU, voices calling for a postponement of the IVD Regulation’s 2022 enforcement date are growing louder.
Medtech Insight: global medical technology news & analysis
10 Jul 2020
An executive VP at UnitedHealth Group is now at the helm at DuPage Medical; GTX Medical gets a new CEO...
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
Looking for more products Product Finder
